Clinical Trial Update: 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma [EARLY_Phase 1]

View source ↗

Summary

An early phase 1 study is evaluating the PET imaging tracer 68Ga-FAPi-46 in patients with sarcoma; the trial is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma

Drugs mentioned

• 68Ga-FAPI-46 (Gallium-68-labeled FAPI-46)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Metastatic Sarcoma, Recurrent Sarcoma | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING